ReviewMediterranean journal of rheumatology2023
Ocular Manifestations of Spondyloarthritis.
Review in Mediterranean journal of rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Uveitis in spondyloarthritis: clinical patterns and differences between axial and peripheral forms.Clinical rheumatology · 2026Observational
- Current and Emerging Therapies for Uveitis in Axial Spondyloarthritis: A Scoping Review.Mediterranean journal of rheumatology · 2026Review
- Dry eye disease in axial spondyloarthritis: heterogeneous ocular surface dysfunction involving tear film instability and tear production from the AIDA network registry.Frontiers in medicine · 2026Article
- Diagnostic Value of Conjunctival Impression Cytology and Nelson Grading in Evaluating Dry Eye Disease in Ankylosing Spondylitis.Medicina (Kaunas, Lithuania) · 2025Article
- Assessment of ocular manifestations in spondyloarthropathies: An observational study.Bioinformation · 2025Article
- Beyond the joints: mechanistic insights and multidisciplinary strategies for spondyloarthritis-associated uveitis.Frontiers in immunology · 2025Review
- Efficacy of biologic and targeted synthetic disease-modifying antirheumatic drugs in non-infectious uveitis in axial spondyloarthropathy and their ocular side effects.Reumatologia · 2025Review
- Treatment of recurrent uveitis and ankylosing spondylitis with Golimumab: a case report, Letter to Editor.Annals of medicine and surgery (2012) · 2024Article
- Time Trend Analysis of Comorbidities in Ankylosing Spondylitis: A Population-Based Study from 53,142 Hospitalizations in Poland.Journal of clinical medicine · 2024Article
- Higher frequency but similar recurrence rate of uveitis episodes in axial spondylarthritis compared to psoriatic arthritis. A multicentre retrospective study.Rheumatology international · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ocular manifestations are seen in several autoimmune disorders including spondyloarthritis (SpAs). Though acute anterior uveitis (AAU) is the hallmark of SpAs, episcleritis and scleritis are also seen. Genetic and geographical factors impact the prevalence of AAU; however, available evidence support that HLA-B27 positivity is closely associated with it. Objective: The current narrative review is focused on clinical features of AAU and its management. Methods: For the purpose of this narrative review; literature search covered MEDLINE, Google scholar and EMBASE databases and included articles published in English language from January 1980 till April 2022 using the following keywords: "Ankylosing spondylitis", "Spondyloarthritis", "Eye manifestations", "Ocular", "Uveitis" and "Arthritis". Conclusion: Patients with SpA may suffer from different ocular complications with uveitis being the most common one. Biological therapy is a promising medical strategy enabling in achieving therapeutic goals with minimal adverse effects. An effective management strategy for patients with AAU associated with SpA could be formulated by the collaboration between ophthalmologists and rheumatologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.